Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 6.16
NAS:ALNY's Cash-to-Debt is ranked lower than
64% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. NAS:ALNY: 6.16 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:ALNY' s Cash-to-Debt Range Over the Past 10 Years
Min: 3.29  Med: No Debt Max: No Debt
Current: 6.16
Equity-to-Asset 0.78
NAS:ALNY's Equity-to-Asset is ranked higher than
57% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:ALNY: 0.78 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:ALNY' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.99  Med: 0.64 Max: 0.92
Current: 0.78
-0.99
0.92
Debt-to-Equity 0.13
NAS:ALNY's Debt-to-Equity is ranked higher than
61% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. NAS:ALNY: 0.13 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:ALNY' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.07  Med: 0.09 Max: 0.33
Current: 0.13
-0.07
0.33
Interest Coverage N/A
NAS:ALNY's Interest Coverage is ranked lower than
54% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:ALNY: N/A )
Ranked among companies with meaningful Interest Coverage only.
NAS:ALNY' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: N/A
N/A
No Debt
Piotroski F-Score: 2
Altman Z-Score: 11.38
Beneish M-Score: -1.86
WACC vs ROIC
21.23%
-109.09%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -680.48
NAS:ALNY's Operating Margin % is ranked lower than
73% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. NAS:ALNY: -680.48 )
Ranked among companies with meaningful Operating Margin % only.
NAS:ALNY' s Operating Margin % Range Over the Past 10 Years
Min: -900.33  Med: -188.54 Max: -28.95
Current: -680.48
-900.33
-28.95
Net Margin % -670.81
NAS:ALNY's Net Margin % is ranked lower than
74% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. NAS:ALNY: -670.81 )
Ranked among companies with meaningful Net Margin % only.
NAS:ALNY' s Net Margin % Range Over the Past 10 Years
Min: -869.63  Med: -163.4 Max: -27.3
Current: -670.81
-869.63
-27.3
ROE % -44.38
NAS:ALNY's ROE % is ranked lower than
52% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. NAS:ALNY: -44.38 )
Ranked among companies with meaningful ROE % only.
NAS:ALNY' s ROE % Range Over the Past 10 Years
Min: -84.12  Med: -39.64 Max: -13.08
Current: -44.38
-84.12
-13.08
ROA % -33.92
NAS:ALNY's ROA % is ranked lower than
52% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. NAS:ALNY: -33.92 )
Ranked among companies with meaningful ROA % only.
NAS:ALNY' s ROA % Range Over the Past 10 Years
Min: -48.05  Med: -23.41 Max: -5.01
Current: -33.92
-48.05
-5.01
ROC (Joel Greenblatt) % -430.43
NAS:ALNY's ROC (Joel Greenblatt) % is ranked lower than
53% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. NAS:ALNY: -430.43 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:ALNY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2120.98  Med: -554.62 Max: -149.42
Current: -430.43
-2120.98
-149.42
3-Year Revenue Growth Rate -10.40
NAS:ALNY's 3-Year Revenue Growth Rate is ranked lower than
68% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:ALNY: -10.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:ALNY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -8.15 Max: 108
Current: -10.4
0
108
3-Year EBITDA Growth Rate 52.70
NAS:ALNY's 3-Year EBITDA Growth Rate is ranked higher than
89% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. NAS:ALNY: 52.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:ALNY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -64.8  Med: 3.5 Max: 65.3
Current: 52.7
-64.8
65.3
3-Year EPS without NRI Growth Rate 48.90
NAS:ALNY's 3-Year EPS without NRI Growth Rate is ranked higher than
90% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. NAS:ALNY: 48.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:ALNY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -66.7  Med: 6.6 Max: 52.8
Current: 48.9
-66.7
52.8
GuruFocus has detected 2 Warning Signs with Alnylam Pharmaceuticals Inc $NAS:ALNY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ALNY's 30-Y Financials

Financials (Next Earnings Date: 2017-11-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

ALNY Guru Trades in Q3 2016

Dodge & Cox 5,276,068 sh (+109.64%)
John Paulson 19,300 sh (unchged)
John Griffin 1,320,000 sh (unchged)
Vanguard Health Care Fund 8,512,270 sh (unchged)
Jim Simons Sold Out
» More
Q4 2016

ALNY Guru Trades in Q4 2016

Dodge & Cox 9,204,950 sh (+74.47%)
Vanguard Health Care Fund 8,549,357 sh (+0.44%)
John Griffin 1,320,000 sh (unchged)
John Paulson 19,300 sh (unchged)
» More
Q1 2017

ALNY Guru Trades in Q1 2017

Jim Simons 51,100 sh (New)
Pioneer Investments 87,256 sh (New)
John Griffin 1,590,000 sh (+20.45%)
Dodge & Cox 9,399,245 sh (+2.11%)
Vanguard Health Care Fund 8,549,357 sh (unchged)
John Paulson Sold Out
» More
Q2 2017

ALNY Guru Trades in Q2 2017

Joel Greenblatt 9,684 sh (New)
George Soros 7,000 sh (New)
Steven Cohen 50,000 sh (New)
Pioneer Investments 147,194 sh (+68.69%)
Jim Simons Sold Out
Dodge & Cox 9,185,820 sh (-2.27%)
Vanguard Health Care Fund 8,047,957 sh (-5.86%)
John Griffin 1,376,700 sh (-13.42%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ALNY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Dodge & Cox 2017-06-30 Reduce -2.27%0.01%$47.75 - $85.21 $ 113.8479%9,185,820
Vanguard Health Care Fund 2017-06-30 Reduce -5.86%0.06%$47.75 - $85.21 $ 113.8479%8,047,957
Joel Greenblatt 2017-06-30 New Buy0.01%$47.75 - $85.21 $ 113.8479%9,684
George Soros 2017-06-30 New Buy0.01%$47.75 - $85.21 $ 113.8479%7,000
Dodge & Cox 2017-03-31 Add 2.11%0.01%$36.88 - $59.71 $ 113.84146%9,399,245
John Paulson 2017-03-31 Sold Out 0.01%$36.88 - $59.71 $ 113.84146%0
Dodge & Cox 2016-12-31 Add 74.47%0.13%$31.41 - $70.3 $ 113.84172%9,204,950
Vanguard Health Care Fund 2016-12-31 Add 0.44%$31.41 - $70.3 $ 113.84172%8,549,357
Dodge & Cox 2016-11-30 Add 71.95%0.16%Premium Member Access $43.87 $ 113.84159%9,072,450
Dodge & Cox 2016-09-30 Add 109.64%0.18%$59.42 - $78.42 $ 113.8461%5,276,068
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:IONS, NAS:TSRO, NAS:SGEN, NAS:BLUE, NAS:BIVV, NAS:EXEL, NAS:UTHR, NAS:NBIX, NAS:JUNO, NAS:TECH, NAS:ACAD, NAS:PBYI, NAS:KITE, NAS:FGEN, NAS:NKTR, NAS:CLVS, NAS:AGIO, NAS:PTLA, NAS:ONCE, NAS:SRPT » details
Traded in other countries:DUL.Germany,
Headquarter Location:USA
Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes.

Alnylam Pharmaceuticals is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class of drugs. Alnylam has partnered several pipeline candidates--including amyloidosis drug patisiran, hemophilia drug fitusiran, and cholesterol drug inclisiran. Upfront fees from research partnerships with firms such as Sanofi, Takeda, Roche, and The Medicines Company have boosted Alnylam's cash levels, and the firm stands to see milestones and royalties from drugs commercialized under these agreements.

Ratios

vs
industry
vs
history
PB Ratio 9.30
ALNY's PB Ratio is ranked lower than
78% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. ALNY: 9.30 )
Ranked among companies with meaningful PB Ratio only.
ALNY' s PB Ratio Range Over the Past 10 Years
Min: 2.07  Med: 4.89 Max: 21.37
Current: 9.3
2.07
21.37
PS Ratio 149.24
ALNY's PS Ratio is ranked lower than
87% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. ALNY: 149.24 )
Ranked among companies with meaningful PS Ratio only.
ALNY' s PS Ratio Range Over the Past 10 Years
Min: 3.1  Med: 21.74 Max: 222.78
Current: 149.24
3.1
222.78
EV-to-EBIT -21.56
ALNY's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. ALNY: -21.56 )
Ranked among companies with meaningful EV-to-EBIT only.
ALNY' s EV-to-EBIT Range Over the Past 10 Years
Min: -61.7  Med: -10.95 Max: -1.3
Current: -21.56
-61.7
-1.3
EV-to-EBITDA -22.12
ALNY's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. ALNY: -22.12 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALNY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -95.7  Med: -11.9 Max: -1.4
Current: -22.12
-95.7
-1.4
EV-to-Revenue 146.54
ALNY's EV-to-Revenue is ranked lower than
83% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. ALNY: 146.54 )
Ranked among companies with meaningful EV-to-Revenue only.
ALNY' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.7  Med: 17.35 Max: 200.5
Current: 146.54
0.7
200.5
Current Ratio 8.84
ALNY's Current Ratio is ranked higher than
65% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. ALNY: 8.84 )
Ranked among companies with meaningful Current Ratio only.
ALNY' s Current Ratio Range Over the Past 10 Years
Min: 1.88  Med: 5.1 Max: 18.24
Current: 8.84
1.88
18.24
Quick Ratio 8.84
ALNY's Quick Ratio is ranked higher than
66% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. ALNY: 8.84 )
Ranked among companies with meaningful Quick Ratio only.
ALNY' s Quick Ratio Range Over the Past 10 Years
Min: 1.88  Med: 5.1 Max: 18.24
Current: 8.84
1.88
18.24
Days Sales Outstanding 85.20
ALNY's Days Sales Outstanding is ranked lower than
78% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. ALNY: 85.20 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALNY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.57  Med: 34.48 Max: 288.31
Current: 85.2
0.57
288.31

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -10.50
ALNY's 3-Year Average Share Buyback Ratio is ranked higher than
55% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. ALNY: -10.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALNY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -331.8  Med: -15.2 Max: -1
Current: -10.5
-331.8
-1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 17.07
ALNY's Price-to-Net-Cash is ranked lower than
83% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. ALNY: 17.07 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ALNY' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.7  Med: 9.38 Max: 92.77
Current: 17.07
3.7
92.77
Price-to-Net-Current-Asset-Value 16.08
ALNY's Price-to-Net-Current-Asset-Value is ranked lower than
85% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. ALNY: 16.08 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ALNY' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.54  Med: 9.2 Max: 82.06
Current: 16.08
3.54
82.06
Price-to-Tangible-Book 9.29
ALNY's Price-to-Tangible-Book is ranked lower than
70% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. ALNY: 9.29 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ALNY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.2  Med: 4.93 Max: 15.16
Current: 9.29
2.2
15.16
Price-to-Median-PS-Value 6.87
ALNY's Price-to-Median-PS-Value is ranked lower than
95% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. ALNY: 6.87 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ALNY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.16  Med: 1.15 Max: 8.91
Current: 6.87
0.16
8.91
Earnings Yield (Greenblatt) % -4.65
ALNY's Earnings Yield (Greenblatt) % is ranked higher than
54% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. ALNY: -4.65 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ALNY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -79.8  Med: -9.1 Max: -1.6
Current: -4.65
-79.8
-1.6

More Statistics

Revenue (TTM) (Mil) $66.00
EPS (TTM) $ -5.11
Beta3.21
Short Percentage of Float20.18%
52-Week Range $31.38 - 89.45
Shares Outstanding (Mil)91.73

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 74 136 206
EPS ($) -5.38 -5.42 -4.37
EPS without NRI ($) -5.38 -5.42 -4.37
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ALNY

Headlines

Articles On GuruFocus.com
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alnylam Pharmaceuti Sep 07 2017 
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmace Sep 07 2017 
7 Outperforming Stocks With Rising Prices Jun 27 2017 
High Return Covered Call Trades for Alnylam Pharmaceuticals, Lumber Liquidators, Nutrisystem, 500.Co Apr 04 2017 
Weekly Top Insider Buys Highlight for Week of Oct. 14 Oct 16 2016 
Low Valuation Ratios Lead to Strong Portfolio Returns Sep 13 2016 
Liberty Broadband, Hanmi Bank Among Popular Micro-Cap Stocks Apr 04 2016 
Weekly Insider Sells Highlights: Facebook, PacWest Bancorp, Waste Management, Alnylam Pharmaceutical Nov 17 2015 
Julian Robertson Boosts His Stakes in JD.com, Netflix Oct 06 2015 
Julian Robertson Adds 16 New Stakes to Portfolio Jun 23 2015 

More From Other Websites
What Happened in the Stock Market Today Sep 20 2017
Here's Why Arbutus Biopharma Corp. Stock Soared Today Sep 20 2017
Alnylam Rockets On Strong Rare-Disease Drug Data; Ionis Tanks Sep 20 2017
Alnylam's RNAi drug succeeds in key study, shares soar Sep 20 2017
Alnylam Notches a Game-Changing RNAi Win Sep 20 2017
Why Alnylam Pharmaceuticals, Inc. Skyrocketed and Ionis Pharmaceuticals Inc Sank Today Sep 20 2017
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Soars on Drug Breakthrough Sep 20 2017
Arbutus’ LNP Licensee Alnylam Announces Positive Phase 3 Results for LNP-Enabled Patisiran Program Sep 20 2017
What's Next for Alnylam Pharmaceuticals, Inc.? Sep 20 2017
After 20 Years, A Drug That Silences Genes Succeeds Sep 20 2017
Cheer Alnylam's Drug, Pause on Its Platform Sep 20 2017
Calamities Couldn't Spoil The Bullish Run Sep 20 2017
Alnylam shares surge 40% on drug results that may herald a new type of medicine Sep 20 2017
Hurricanes, Earthquakes and Record-High Markets Sep 20 2017
Alnylam Shares Skyrocket on Clinical Study Results - Biotech Movers Sep 20 2017
Why Alnylam Pharmaceuticals Inc (ALNY) Could Be A Buy Sep 20 2017
UPDATE: Alnylam shares jump 24% on positive results from late-stage trial of hATTR amyloidosis... Sep 20 2017
Alnylam's genetic disease drug meets main goal in key study Sep 20 2017
Sanofi and Alnylam Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in... Sep 20 2017
Alnylam and Sanofi Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in... Sep 20 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}